DAIC

APRIL 6, 2024

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81

Stroke Journal

FEBRUARY 1, 2024

Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.

Diabetes 40

Diabetes Stroke Strokes Kidney Disease 40

DAIC

APRIL 30, 2024

The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include heart and chronic kidney disease and heightened cardiovascular risk.

Heart Failure 105

Heart Failure Hospital Research COVID-19 105

Open Heart

JULY 20, 2022

Outcome measures were (1) all-cause hospitalisations, (2) outpatient clinic attendances and (3) cost. Multispecialty interventions included optimising diabetes therapy (haemoglobin A1c-HbA1c pre-MDT 68±11 mmol/mol vs post-MDT 61±9 mmol/mol; p<0.001), deprescribing to reduce anticholinergic burden (pre-MDT 1.85±0.4

Heart Failure 52

Heart Failure Kidney Disease Outpatient Nursing 52

Circulation

NOVEMBER 11, 2024

Patient did not report any symptoms and was hemodynamically stable. He was euvolemic on physical exam.

Bradycardia 40

Bradycardia Coronary Artery Disease Kidney Disease Outpatient 40

Open Heart

SEPTEMBER 27, 2023

Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. In multivariable analyses, we identified risk factors for developing the third condition and mortality, such as age, sex, medical history and the order of disease diagnosis.

Risk Factors 52

Risk Factors Kidney Disease Heart Failure Diabetes 52